Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 17/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | HTR6 | P50406 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-242084 SCHEMBL29388888 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-242084 SCHEMBL29462298 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-242084 SCHEMBL18395254 | 0.99 | HTR2C (0.98) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-242084 SCHEMBL18953108 | 0.98 | HTR2C (0.97) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL7361498 | 0.95 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL6304598 | 0.88 | HTR2C (0.78) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-243213 SCHEMBL31060820 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-243213 SCHEMBL29697170 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-243213 SCHEMBL677610 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ANPC1MTOR | |
| Sb-243213 SCHEMBL7473195 | 0.86 | HTR2C (0.98) | HTR2CHTR2BHTR2ANPC1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003011281-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER OR ATTENTION DEFICIT DISORDER | VERNALIS RESEARCH LIMITED (GB) | 2003-02-13 | — | — | WO | claimed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20180311499-A1 | Treatment of Dermatological Conditions via Neuromodulation | PALO ALTO INVESTORS | 2018-11-01 | — | — | US | disclosed |
| US-9655906-B2 | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-05-23 | — | — | US | disclosed |
| WO-2016205631-A1 | SEROTONIN 2C RECEPTOR ANTAGONISTS TO PREVENT AND TREAT STRESS-RELATED TRAUMA DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-22 | — | — | WO | disclosed |
| US-20150320763-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F S.P.A. (IT) | 2015-11-12 | — | — | US | disclosed |
| US-9120801-B2 | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2015-09-01 | — | — | US | disclosed |
| EP-2556074-B1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | ACRAF (IT) | 2015-01-21 | — | — | EP | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8680091-B2 | 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028131-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028082-A1 | 6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1534258-A2 | AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | Wyeth (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063721-A1 | Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction | WYETH | 2004-04-01 | — | — | US | disclosed |
| WO-2004016256-A2 | AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | WYETH (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003057161-A2 | BENZOTHIENO [3,2-c]PYRAZOLYL AND BENZOFURANO [3,2-c] PYRAZOLYL COMPOUNDS, THEIR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR AND INTERMEDIATE COMPOUNDS THEREOF | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003011281-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER OR ATTENTION DEFICIT DISORDER | VERNALIS RESEARCH LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320763-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | CYP3A43, CYP3A4, CYP3A5 | HTR2C 400/4885HTR2B 759/4885HTR2A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.